Merz Pharmaceuticals, LLC Sustainability Profile
Merz Pharmaceuticals, LLC, a prominent player in the global healthcare landscape, is headquartered in the United States. Founded in 1908, the company has established itself as a leader in the pharmaceutical and aesthetics industries, focusing on innovative solutions for neurology, dermatology, and aesthetic medicine. With a strong presence in North America and Europe, Merz Pharmaceuticals is renowned for its core products, including the well-regarded Xeomin® and Belotero® lines, which offer unique benefits in the realm of injectables. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in patient care. Merz Pharmaceuticals continues to excel in delivering high-quality, effective treatments, solidifying its market position through a dedication to innovation and excellence in the healthcare sector.
DitchCarbon Score
How does Merz Pharmaceuticals, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharmaceuticals, LLC's score of 29 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merz Pharmaceuticals, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Merz Pharma GmbH & Co. KGaA, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Merz Pharmaceuticals, LLC. The absence of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. Given the lack of direct emissions data, it is important to note that Merz Pharmaceuticals, LLC's climate commitments may be informed by the broader initiatives of its parent company, Merz Pharma GmbH & Co. KGaA. However, specific details regarding these initiatives or any cascading emissions data from the parent organisation have not been provided. In summary, while Merz Pharmaceuticals, LLC is part of a larger corporate family that may have climate commitments, there is currently no available data on its carbon emissions or specific reduction targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 2,088,000 | 0,000,000 |
| Scope 2 | 771,000 | 000,000 |
| Scope 3 | 36,782,000 | 00,000,000 |
How Carbon Intensive is Merz Pharmaceuticals, LLC's Industry?
How Carbon Intensive is Merz Pharmaceuticals, LLC's Location?
Merz Pharmaceuticals, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Merz Pharmaceuticals, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
